Response to letter to the editor: switch to dolutegravir and unboosted atazanavir

AIDS. 2019 Nov 15;33(14):2263-2264. doi: 10.1097/QAD.0000000000002330.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-HIV Agents*
  • Atazanavir Sulfate
  • HIV Infections*
  • HIV-1*
  • Heterocyclic Compounds, 3-Ring
  • Humans
  • Oxazines
  • Piperazines
  • Pyridones
  • Viral Load

Substances

  • Anti-HIV Agents
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • Atazanavir Sulfate
  • dolutegravir